Sachetta LLC Sells 296 Shares of Gilead Sciences, Inc. $GILD

Sachetta LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 43.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 383 shares of the biopharmaceutical company’s stock after selling 296 shares during the period. Sachetta LLC’s holdings in Gilead Sciences were worth $42,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the 1st quarter worth $25,000. Activest Wealth Management increased its stake in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Goodman Advisory Group LLC bought a new position in Gilead Sciences during the 1st quarter worth $29,000. Colonial Trust Advisors increased its stake in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares during the period. Finally, Core Alternative Capital increased its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 241 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Saturday, September 27th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Rothschild & Co Redburn raised their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Royal Bank Of Canada raised their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $116.78 on Wednesday. The company has a market cap of $144.90 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a 50-day simple moving average of $114.41 and a 200-day simple moving average of $110.06.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the company earned $2.01 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,000 shares of company stock valued at $9,402,130. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.